STOCK TITAN

Aditxt Inc - ADTX STOCK NEWS

Welcome to our dedicated news page for Aditxt (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aditxt's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aditxt's position in the market.

Rhea-AI Summary
Aditxt provides update on innovation programs and strategic M&A initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
-
Rhea-AI Summary
Aditxt announces 1-for-40 reverse stock split to comply with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.58%
Tags
none
-
Rhea-AI Summary
Aditxt, Inc. (NASDAQ: ADTX) announces a 1-for-40 reverse stock split effective on August 18, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.58%
Tags
none
Rhea-AI Summary
Aditxt, a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed a non-binding Letter of Intent to acquire Natural State Laboratories and Natural State Genomics. The acquisition would support revenue growth and provide Pearsanta with an expanded management team. The consideration for the transaction is not to exceed $55 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
acquisition
-
Rhea-AI Summary
Aditxt's subsidiary Adimune has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases of the central nervous system (CNS), starting with Stiff Person Syndrome (SPS). The collaboration aims to restore immune tolerance in patients with progressive autoimmune CNS disorders. The clinical trial is expected to begin in 2023 with enrollment of approximately 10-15 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.44%
Tags
offering
-
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
Aditxt Inc

Nasdaq:ADTX

ADTX Rankings

ADTX Stock Data

5.66M
433.89k
9.43%
6.06%
2.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Richmond

About ADTX

a biotech company with a mission to accelerate humanity’s transition to the "age of immunity", we are the business busily decoding the human immune system.